FDA Approves Pembrolizumab for HCC

November 9, 2018 – The FDA has granted pembrolizumab an accelerated approval for the treatment of patients with hepatocellular carcinoma (HCC) who have previously received sorafenib, according to Merck (MSD), the manufacturer of the PD-1 inhibitor. The approval is based on findings from the phase II KEYNOTE-224 trial, in which single-agent pembrolizumab induced an overall response rate (ORR) of 17% (95% CI, 11-26) among 104 patients with … (leggi tutto)